|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond显示文摘Irritable bowel syndrome(IBS)is a chronic,recurring,and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain,distention,and changes in bowel habits.Although there are several drugs for IBS,effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed.Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism,neurohormonal regulation,immune dysfunction,the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS.With regards to therapies for restoring intestinal permeability,multiple studies with prebiotics and probiotics are ongoing,even if to date their efficacy has been limited.In parallel,much progress has been made in targeting low-grade inflammation,especially through the introduction of drugs such as mesalazine and rifaximin,even if a better knowledge of the mechanisms underlying the low-grade inflammation in IBS may allow the design of clinical trials that test the efficacy and safety of such drugs.This literature review aims to summarize the findings related to new and investigational therapeutic agents for IBS,most recently developed in preclinical as well as Phase 1 and Phase 2clinical studies. | Emanuele Sinagra Gaetano Cristian Morreale Ghazaleh Mohammadian Giorgio Fusco Valentina Guarnotta Giovanni Tomasello Francesco Cappello Francesca Rossi Georgios Amvrosiadis Dario Raimondo | 2017 | World Journal of Gastroenterology2017，23，36： | 14 |
| 2 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists显示文摘Management of cancers of the digestive system has progressed rapidly into the molecular era. Despite the significant recent achievements in the diagnosis and treatment of these patients, the number of deaths for these tumors has currently plateaued. Many investigations have assessed the role of HER2 in tumors of the digestive system in both prognostic and therapeutic settings, with heterogeneous results. Novel testing and treatment guidelines are emerging, in particular in gastric and colorectal cancers. However, further advances are needed. In this review we provide a comprehensive overview of the current state-ofknowledge of HER2 alterations in the most common tumors of the digestive system and discuss the operational implications of HER2 testing. | Nicola Fusco Silvano Bosari | 2016 | World Journal of Gastroenterology2016，22，35： | 5 |
| 3 | Studies on abacavir-induced hypersensitivity reaction:a successful example of translation of pharmacogenetics to personalized medicine显示文摘Abacavir is an effective nucleoside analog reverse transcriptase inhibitor used to treat human immunodeficiency virus(HIV) infected patients.Its main side effect is hypersensitivity reaction(HSR).The incidence of the HSR is associated with ethnicity among patients exposed to abacavir,and retrospective and prospective studies show a significantly increased risk of abacavir-induced HSR in human leukocyte antigen(HLA)-B*57:01-carrying patients.Immunological studies indicated that abacavir interacts specifically with HLA-B*57:01 and changed the binding specificity between the HLA molecule and the HLA-presented endogenous peptide repertoire,leading to a systemic autoimmune reaction.HLA-B*57:01 screening,combined with patch testing,had clinically predictive value and cost-effective impact in reducing the incidence of abacavir-induced HSR regardless of the HLA-B*57:01 prevalence in the population.Therefore,the US Food and Drug Administration(FDA) and international HIV treatment guidelines recommend a routine HLA-B*57:01 screening prior to abacavir treatment to decrease false positive diagnosis and prevent abacavir-induced HSR.The studies of abacavir-induced HSR and the implementation of the HLA-B*57:01 screening in the clinic represent a successful example of the use of pharmacogenetics for personalized diagnosis and therapy. | GUO YongLi SHI LeMing HONG HuiXiao SU ZhenQiang FUSCOE James NING BaiTang | 2013 | Science China(Life Sciences)2013，56，2： | 3 |
| 4 | Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy显示文摘AIM To report early imaging assessment of ablated area post electrochemotherapy(ECT) in patients with locally advanced pancreatic cancer(LAPC). METHODS ECT was performed in 19 LAPC patients enrolled in an approved ongoing clinical phase Ⅰ/Ⅱ study. Before and after ECT, 18 patients underwent computed tomography(CT) scan, 11 patients underwent morphological and functional magnetic resonance(MR) scan(dynamic contrast enhanced-MRI) calculating wash-in slope(WIS) and wash-out slope(WOS); diffusion weighted imaging calculating pseudo-diffusivity(Dp), perfusion fraction(fp) and tissue diffusivity(Dt); 10 patients underwentpositron emission tomography(PET). Response evaluation criteria in solid tumour(RECIST) on MR and CT were used to assess tumour therapy response. Choi on CT, PET response criteria in solid tumors(PERCIST) on PET and functional parameters on MR were used to evaluate treatment response.RESULTS For each patient no significant reduction was measurable by CT and MR using RECIST. According Choi criteria a partial response was obtained in 18/18(100.0%) patients. According PERCIST criteria 6/10(60.0%) patients showed a partial response, 3/10(30.0%) stable disease and 1/10(10.0%) progression disease. Moreover, using functional MR parameters, a significant reduction of viable tumour after ECT can be observed. According ΔWIS and ΔWOS 9/11(81.8%) patients exhibited a partial response and 2/11(18.2%) stable disease; 8/11(72.7%) patients were considered in partial response by ΔDp evaluation and 3/11(27.3%) in stable disease; according ΔDt 7/11(63.6%) patients showed a partial response, 1/11(9.1%) showed progression of disease and 3/11(27.3%) were stable. Perfusion fraction fp showed a significant reduction after ECT only in four patients. No significant difference was observed after ECT in signal intensity of T1-weighted images and T2-weighted images, and in equilibrium-phase of contrast study, according to χ2 test was observed. A good correlation was reported between ΔHounsfield unit and Δmaximum standardized uptake value and between Δfp and ΔWOS, with a significant statistically difference(P < 0.05) using Spearman correlation coefficient.CONCLUSION Perfusion and diffusion MR derived parameters, Choi, PERCIST criteria are more performant than morphological MR and CT criteria to assess ECT treatment response. | Vincenza Granata Roberta Fusco Sergio Venanzio Setola Mauro Piccirillo Maddalena Leongito Raffaele Palaia Francesco Granata Secondo Lastoria Francesco Izzo Antonella Petrillo | 2017 | World Journal of Gastroenterology2017，23，26： | 3 |
| 5 | Nuclear imaging in detection and monitoring of cardiotoxicity显示文摘Cardiotoxicity as a result of cancer treatment is a novel and serious public health issue that has a significant impact on a cancer patient’s management and outcome.The coexistence of cancer and cardiac disease in the same patient is more common because of aging population and improvements in the efficacy of antitumor agents.Left ventricular dysfunction is the most typical manifestation and can lead to heart failure.Left ventricular ejection fraction measurement by echocardiography and multigated radionuclide angiography is the most common diagnostic approach to detect cardiac damage,but it identifies a late manifestation of myocardial injury.Early non-invasive imaging techniques are needed for the diagnosis and monitoringof cardiotoxic effects.Although echocardiography and cardiac magnetic resonance are the most commonly used imaging techniques for cardiotoxicity assessment,greater attention is focused on new nuclear cardiologic techniques,which can identify high-risk patients in the early stage and visualize the pathophysiologic process at the tissue level before clinical manifestation.The aim of this review is to summarize the role of nuclear imaging techniques in the non-invasive detection of myocardial damage related to antineoplastic therapy at the reversible stage,focusing on the current role and future perspectives of nuclear imaging techniques and molecular radiotracers in detection and monitoring of cardiotoxicity. | Carmen D’Amore Paola Gargiulo Stefania Paolillo Angela Maria Pellegrino Tiziana Formisano Antonio Mariniello Giuseppe DellaRatta Elisabetta Iardino Marianna D’Amato Lucia La Mura Irma Fabiani Flavia Fusco Pasquale Perrone Filardi | 2014 | World Journal of Radiology2014，6，7： | 2 |
| 6 | 意大利临床实践中的PDE5抑制剂治疗模式:“勃起功能障碍观测研究”的纵向数据显示文摘“勃起功能障碍观测研究”(Erectile Dysfunction Observational Study,EDOS)是一项为期6个月的多中心前瞻性研究,研究对象包括被要求开始接受治疗或改变治疗方式的ED病人。本研究旨在分析ED的治疗模式,并比较不同治疗模式的疗效。研究对象为到医院看病并诊断需要进行ED治疗的患者。他们接受ED治疗,并在治疗开始时、治疗3个月、6个月时回答来自IIEF(International Index of Erectile Function),EDITS(Erectile Dysfunction Inventory of Treatment Satisfaction),SF-PAIRS(Short Form of the Psychological and Interpersonal Relationship Scale)/nq卷的问题。医生可以给病人开出市场上现有的任何疗法,并可以在治疗过程中任何时间改变疗法。在完成为期6个月的分析的1338名病人中,有624人(47%)改变了疗法,714人(53%)一直接受最初诊断的疗法,其中接受治疗的病人持续接受一种疗法的比率显著高于接受西地那非或伐地那非治疗的病人。其它影响这一比率的变量包括性欲低下和ED。各种PDE-5抑制剂在效力、病人满意度、自信心、自发性等方面无显著差异。接受他达拉非治疗的病人的SF—PAIRS“时间相关”项的分数显著优于接受其它治疗的病人。结果显示现有的三种PDE-5抑制剂的临床实践和临床实验结果相似,但病人如果要终止或改变用药,他达拉非的风险较低。 | Ferdinando Fusco Riccardo Sicuteri Andrea Rossi Stathis Kontodimas Jose Maria Haro Ciro Imbimbo 无 | 2009 | Asian Journal of Andrology2009，11，5： | 2 |
| 7 | Fever of unknown origin:a systematic review of the literature for 1995-2004 显示文摘 | GAETA G B FUSCO F M NARDIELLO S | 2006 | Nucl Med Commun2006，27，3： | 1 |
| 8 | Benign Infantile Familial Convulsions显示文摘 | Vigevano F Fusco L Dicapua M | 1992 | Eur J Pediatr1992，151，3： | 1 |
| 9 | Long-term results of small intestinal submucosa graft in bulbar urethral reconstruction 显示文摘 | Palminteri E Berdondini E Fusco F | 2012 | Urology2012，79，： | 1 |
| 10 | Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance显示文摘 | Ranieri SC Fusco S Panieri E | 2010 | Proc Natl Acad Sci U S A2010，107，13： | 1 |
| 11 | Echinacea purpurea aerial extract alters course of influenza infection in mice显示文摘 | Fusco Dahlene Liu Xinyan Savage Caroline | 2010 | Vaccine2010，，28： | 1 |
| 12 | IL-21 as a therapeutic target in inflammatory disorders显示文摘 | Di Fusco D Izzo R Figliuzzi M M | 2014 | Expert Opin Ther Targets2014，18，11： | 1 |
| 13 | Increased shoe bending stiffness increases sprint perform- ance 显示文摘 | Stefanyshyn D Fusco C | 2004 | Sports Biomech2004，3，1： | 1 |
| 14 | HMGA and cancer 显示文摘 | Fedele M Fusco A | 2010 | Biochim Biophys Acta2010，1799，12： | 1 |
| 15 | Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma 显示文摘 | Rose PG Mossbruger K Fusco N | 2003 | Gynecol Oncol2003，88，1： | 1 |
| 16 | Video/EEG aspects of earlyinfantile epileptic encephalopathy with suppression- bursts (Ohtahara syndrome)显示文摘 | Fusco I Pachatz C Di Capua M | 2001 | Brain Dev2001，23，7： | 1 |
| 17 | Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor 显示文摘 | Lee JE Fusco ML Hessell AJ et O1 | 2008 | Nature2008，454，7201： | 1 |
| 18 | Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study 显示文摘 | Ciccacci C Di Fusco D Marazzi MC | 2013 | Eur J Clin Pharmacol2013，69，11： | 1 |
| 19 | A vector approach for the analysis and synthesis of directional modulation transmitters显示文摘 | DING Y FUSCO V F | 2014 | Antennasand Propagation IEEE Transactions on2014，62，1： | 1 |
| 20 | HMGA and cancer 显示文摘 | Fedele M Fusco A | 2010 | Biochim Bio-phys Acta2010，1799，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员